<?xml version='1.0' encoding='utf-8'?>
<document id="9855321"><sentence text="Pharmacokinetics of dexamethasone and valspodar, a P-glycoprotein (mdr1) modulator: implications for coadministration."><entity charOffset="20-33" id="DDI-PubMed.9855321.s1.e0" text="dexamethasone" /></sentence><sentence text="To assess the potential for a drug-drug interaction between valspodar, a P-glycoprotein (mdrl) modulator used as a chemotherapy adjunct, and dexamethasone, widely included in oncology antiemetic regimens"><entity charOffset="141-154" id="DDI-PubMed.9855321.s2.e0" text="dexamethasone" /></sentence><sentence text="" /><sentence text="Randomized, open-label, three-period crossover study" /><sentence text="" /><sentence text="Clinical pharmacology research center" /><sentence text="" /><sentence text="Eighteen healthy men volunteers (age 25" /><sentence text="8+/-3" /><sentence text="5 yrs, weight 71" /><sentence text="6+/-10" /><sentence text="3 kg)" /><sentence text="" /><sentence text="Subjects received single fasting oral doses of valspodar 400 mg, dexamethasone 8 mg, and both drugs concomitantly with 2- to 3-week washout phases between administrations"><entity charOffset="65-78" id="DDI-PubMed.9855321.s14.e0" text="dexamethasone" /></sentence><sentence text="" /><sentence text="Lack of a pharmacokinetic drug-drug interaction with respect to valspodar was conclusively demonstrated for both Cmax,b (2" /><sentence text="3+/-0" /><sentence text="4 vs 2" /><sentence text="4+/-0" /><sentence text="5 microg/ml) and AUCb (19" /><sentence text="8+/-4" /><sentence text="8 vs 19" /><sentence text="6+/-4" /><sentence text="9 microg x hr/ml) inasmuch as bioequivalence criteria were satisfied when comparing administration alone with coadministration, respectively" /><sentence text=" Although no changes in the rate of dexamethasone absorption were noted on coadministration with valspodar (Cmax 88+/-23 vs 91+/-20 ng/ml), overall exposure was significantly increased by 24% on average (AUC 400+/-87 vs 494+/-90 ng x hr/ml)"><entity charOffset="36-49" id="DDI-PubMed.9855321.s25.e0" text="dexamethasone" /></sentence><sentence text=" Regression analysis of valspodar Cmax,b and AUCb during coadministration versus the extent of the interaction (percentage increase in dexamethasone AUC) did not reveal a concentration-effect relationship (p=0"><entity charOffset="135-148" id="DDI-PubMed.9855321.s26.e0" text="dexamethasone" /></sentence><sentence text="7299 and 0" /><sentence text="9718, respectively)" /><sentence text="" /><sentence text="Given dexamethasone's wide therapeutic index and the short duration of coadministration foreseen for these drugs in a clinical setting (maximum 1 wk/chemotherapy cycle), the 24% increase in dexamethasone's AUC is unlikely to be relevant" /><sentence text=" Thus no alterations in valspodar or dexamethasone dosages appear warranted when the two drugs are coadministered"><entity charOffset="37-50" id="DDI-PubMed.9855321.s31.e0" text="dexamethasone" /></sentence><sentence text=" Multiple-dose experience in patients would be desirable to confirm these conclusions" /><sentence text="" /></document>